Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2009 1
2013 1
2014 5
2015 3
2016 3
2017 2
2018 1
2019 1
2020 4
2021 3
2022 2
2023 4
2024 4
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study.
Provenzano L, Dieci MV, Curigliano G, Giuliano M, Botticelli A, Lambertini M, Rizzo G, Pedersini R, Sirico M, La Verde N, Gennari A, Zambelli A, Toss A, Piras M, Giordano M, Tagliaferri B, Generali D, Sartori D, Miliziano D, Menichetti A, Ligorio F, Zurlo C, Griguolo G, Berton Giachetti PP, Faso V, Corti C, Chiappe E, Scagnoli S, Pisegna S, Capasso C, De Angelis C, Arpino G, Criscitiello C, Guarneri V, Pruneri G, Mariani L, Vernieri C; PALMARES-2 Study Group. Provenzano L, et al. Ann Oncol. 2025 Jul;36(7):762-774. doi: 10.1016/j.annonc.2025.03.023. Epub 2025 Apr 8. Ann Oncol. 2025. PMID: 40204155 Free article.
PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer.
Azad A, Arshad M, Generali D, Feldinger K, Gijsen M, Strina C, Cappelletti M, Andreis D, Leek R, Haider S, Kellokumpu-Lehtinen PL, Roxanis I, Harris AL, Shaaban AM, Joensuu H, Kong A. Azad A, et al. Among authors: strina c. Cancer Commun (Lond). 2025 Jan;45(1):68-73. doi: 10.1002/cac2.12632. Epub 2024 Nov 24. Cancer Commun (Lond). 2025. PMID: 39582148 Free PMC article. No abstract available.
Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis.
Schettini F, Nucera S, Di Grazia G, Giudici F, Strina C, Milani M, Tancredi R, Conte B, Criscitiello C, Giuliano M, Lambertini M, Sánchez-Bayona R, Pascual T, Arpino G, Del Mastro L, Vigneri P, Cristofanilli M, Rugo HS, Gennari A, Curigliano G, Generali D. Schettini F, et al. Among authors: strina c. JNCI Cancer Spectr. 2025 Sep 1;9(5):pkaf083. doi: 10.1093/jncics/pkaf083. JNCI Cancer Spectr. 2025. PMID: 40796258 Free PMC article.
Next-generation sequencing-based evaluation of the actionable landscape of genomic alterations in solid tumors: the "MOZART" prospective observational study.
Schettini F, Sirico M, Loddo M, Williams GH, Hardisty KM, Scorer P, Thatcher R, Rivera P, Milani M, Strina C, Ferrero G, Ungari M, Bottin C, Zanconati F, de Manzini N, Aguggini S, Tancredi R, Fiorio E, Fioravanti A, Scaltriti M, Generali D. Schettini F, et al. Among authors: strina c. Oncologist. 2025 Jan 17;30(1):oyae206. doi: 10.1093/oncolo/oyae206. Oncologist. 2025. PMID: 39177668 Free PMC article.
Computational reactive-diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib.
Schettini F, De Bonis MV, Strina C, Milani M, Ziglioli N, Aguggini S, Ciliberto I, Azzini C, Barbieri G, Cervoni V, Cappelletti MR, Ferrero G, Ungari M, Locci M, Paris I, Scambia G, Ruocco G, Generali D. Schettini F, et al. Among authors: strina c. Sci Rep. 2023 Jul 24;13(1):11951. doi: 10.1038/s41598-023-38760-z. Sci Rep. 2023. PMID: 37488154 Free PMC article. Clinical Trial.
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
Fabi A, Carbognin L, Botticelli A, Paris I, Fuso P, Savastano MC, La Verde N, Strina C, Pedersini R, Guarino S, Curigliano G, Criscitiello C, Raffaele M, Beano A, Franco A, Valerio MR, Verderame F, Fontana A, Haspinger ER, Caldara A, Di Leone A, Tortora G, Giannarelli D, Scambia G. Fabi A, et al. Among authors: strina c. NPJ Breast Cancer. 2023 Sep 8;9(1):73. doi: 10.1038/s41523-023-00579-2. NPJ Breast Cancer. 2023. PMID: 37684252 Free PMC article.
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
Fabi A, Carbognin L, Botticelli A, Paris I, Fuso P, Savastano MC, La Verde N, Strina C, Pedersini R, Guarino S, Curigliano G, Criscitiello C, Raffaele M, Beano A, Franco A, Valerio MR, Verderame F, Fontana A, Haspinger ER, Caldara A, Di Leone A, Tortora G, Giannarelli D, Scambia G. Fabi A, et al. Among authors: strina c. NPJ Breast Cancer. 2023 Oct 30;9(1):89. doi: 10.1038/s41523-023-00596-1. NPJ Breast Cancer. 2023. PMID: 37903774 Free PMC article. No abstract available.
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry.
Garrigós L, Saura C, Martinez-Vila C, Zambelli A, Bower M, Pistilli B, Lambertini M, Ottaviani D, Diamantis N, Lumsden A, Pernas S, Generali D, Seguí E, Viñas G, Felip E, Sanchez A, Rizzo G, Santoro A, Cortellini A, Perone Y, Chester J, Iglesias M, Betti M, Vincenzi B, Libertini M, Mazzoni F, Zoratto F, Berardi R, Guida A, Wuerstlein R, Loizidou A, Sharkey R, Aguilar Company J, Matas M, Saggia C, Chiudinelli L, Colomba-Blameble E, Galazi M, Mukherjee U, Van Hemelrijck M, Marin M, Strina C, Prat A, Pla H, Ciruelos EM, Bertuzzi A, Del Mastro L, Porzio G, Newsom-Davis T, Ruiz I, Delany MB, Krengli M, Fotia V, Viansone A, Chopra N, Romeo M, Salazar R, Perez I, d'Avanzo F, Franchi M, Milani M, Pommeret F, Tucci M, Pedrazzoli P, Harbeck N, Ferrante D, Pinato DJ, Gennari A. Garrigós L, et al. Among authors: strina c. Ther Adv Med Oncol. 2021 Nov 2;13:17588359211053416. doi: 10.1177/17588359211053416. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 34777582 Free PMC article.
37 results